SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

25 Jul 2017 07:00

RNS Number : 9436L
Victrex PLC
25 July 2017
 
 

 

 

25 July 2017

 

Victrex plc: Interim Management Statement

 'Continued growth; well-placed for FY17'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2017.

The Group has performed well since the end of the first half and cash generation has continued to be strong.

 

Although the second half sees a tougher volume comparative, particularly for Q4, our core business has remained in good growth, with Automotive, Electronics (ex-Consumer) and Value Added Resellers being notably strong. As expected, whilst we saw some Consumer Electronics volumes during Q3, these were lower than the prior year.

 

In Medical, the mature US Spine market continues to be a challenge to short term-growth although Q3 performance was slightly ahead of the prior year in constant currency. Pleasingly, our differentiated and innovative PEEK-OPTIMATM HA Enhanced product, a premium and next generation offering which promotes bone-on growth, has now secured first meaningful revenues of over £1m and adoption rates are progressing.

 

Overall, Q3 Group revenue* was up 26% to £76.3m (Q3 2016: £60.6m), with Group sales volume up 6% to 1,022 tonnes (Q3 2016: 966 tonnes). Year to date Group sales volume of 2,881 tonnes is 5% up on the prior year (2016 YTD: 2,736 tonnes), with year to date Group revenue of £207.3m up 17% (2016 YTD: £177.6m).

Currency continues to support top-line revenues, with hedges placed at more favourable currency rates benefiting us during the second half year. The anticipated currency benefit for our 2017 financial year is unchanged, and is expected to be weighted approximately one-third/two-thirds between the first and second half. For 2018, we are now over 60% covered for our currency hedging programme.

 

In our growth pipeline, as well as meaningful revenue for PEEK-OPTIMATM HA Enhanced, several 2017 milestones have now been delivered. In Automotive, in addition to our agreement to supply PEEK Gears to a major European Automotive manufacturer from 2018, we now have several new market-wide development programmes with global manufacturers. In Aerospace, construction of our US manufacturing facility is progressing for our TxV Aero Composites joint venture, following pre-qualification of our differentiated grades for loaded brackets last year. We are also developing some strategic alliances in the Aerospace supply chain, as part of our focus on composite parts, to complement this joint-venture.

 

Outlook

For the remainder of 2017, Consumer Electronics volumes are now expected to be lower than our previous guidance, although market-wide engagement programmes are progressing, offering both volume and value opportunities for 2018, including for differentiated applications. Overall, our strong core business performance is more than offsetting lower Consumer Electronics and may now offer a degree of upside potential for the full year. Victrex remains well placed for 2017 and we continue to be comfortable with current expectations.

 

For the medium to longer term, Victrex remains in a good position, with a Polymer & Parts strategy to increase our differentiation, a strong pipeline of potentially game-changing projects, a focus on cost efficiency and a highly cash generative business model.

 

 

Notes:

 

*Q3 and YTD revenue for FY 2017 includes sales from the Zyex PEEK fibres acquisition (completed in April 2017).

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

 

Teneo Blue Rubicon:

Charles Armitstead +44 (0) 207 260 2700

 

 

Analyst & investor conference call

A conference call for analysts & investors will be held today at 08.30 BST. Dial in details: +44 (0) 203 139 4830, pin 54398114#

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 35 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPGUWPMUPMGQC
Date   Source Headline
4th Jun 20208:54 amRNSAdditional Listing
3rd Jun 20202:52 pmRNSHolding(s) in Company
1st Jun 20202:33 pmRNSBlock listing Interim Review
29th May 202011:58 amRNSTotal Voting Rights
21st May 20203:14 pmRNSHolding(s) in Company
19th May 202010:31 amRNSDirector/PDMR Shareholding
18th May 202010:19 amRNSDirector Declaration
11th May 20207:00 amRNSVictrex plc Interim Results
5th May 20204:13 pmRNSDisclosure of Rights Attached to Equity Shares
5th May 20209:00 amRNSDirector Declaration
30th Apr 202011:39 amRNSTotal Voting Rights
17th Apr 202012:04 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSMarket Update
3rd Apr 20207:00 amRNSDirector Declaration
31st Mar 20209:22 amRNSTotal Voting Rights
24th Mar 20202:00 pmRNSDirectorate Change
17th Mar 20203:32 pmRNSHolding(s) in Company
17th Mar 20202:52 pmRNSDirector/PDMR Shareholding
16th Mar 202010:05 amRNSHolding(s) in Company
12th Mar 202012:47 pmRNSDirector/PDMR Shareholding
3rd Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 202011:56 amRNSTotal Voting Rights
20th Feb 20204:50 pmRNSDirector/PDMR Shareholding
13th Feb 20201:59 pmRNSDirector/PDMR Shareholding
6th Feb 20202:34 pmRNSDirector/PDMR Shareholding
6th Feb 20201:20 pmRNSResult of AGM
6th Feb 202010:54 amRNSDirector/PDMR Shareholding
6th Feb 20207:00 amRNSAGM and Q1 Interim Management Statement
5th Feb 20204:22 pmRNSHolding(s) in Company
4th Feb 20203:42 pmRNSHolding(s) in Company
31st Jan 202010:39 amRNSTotal Voting Rights
20th Jan 202010:04 amRNSDirector/PDMR Shareholding
17th Jan 202010:38 amRNSDirector/PDMR Shareholding
13th Jan 20204:06 pmRNSHolding(s) in Company
13th Jan 20208:46 amRNSJoint Venture
3rd Jan 202012:00 pmRNSAnnual Financial Report
31st Dec 20199:00 amRNSTotal Voting Rights
23rd Dec 20191:44 pmRNSHolding(s) in Company
17th Dec 20192:20 pmRNSDirector/PDMR Shareholding
12th Dec 201910:04 amRNSDirector/PDMR Shareholding
5th Dec 20197:00 amRNSPreliminary Results 2019
2nd Dec 20191:52 pmRNSBlock listing Interim Review
29th Nov 201911:38 amRNSTotal Voting Rights
19th Nov 201911:02 amRNSDirector/PDMR Shareholding
12th Nov 201912:00 pmRNSDirectorate Change
31st Oct 201911:36 amRNSTotal Voting Rights
28th Oct 20191:41 pmRNSHolding(s) in Company
18th Oct 20194:01 pmRNSHolding(s) in Company
18th Oct 20192:20 pmRNSDirector/PDMR Shareholding
16th Oct 201911:04 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.